Delayed Development of Hemolytic Anemia with Fragmented Red Blood Cells and Cardiac and Renal Impairments after High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma

Acta Haematol. 2017;138(3):152-161. doi: 10.1159/000480288. Epub 2017 Oct 4.

Abstract

Among 42 consecutive patients with malignant lymphoma who underwent high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (AHSCT), 5 developed hemolytic anemia with fragmented red blood cells (HA-FrRBCs) on days 87-125 (median 107) of AHSCT. Nadir Hb levels ranged between 5.0 and 6.4 g/dL with 2.2-5.6% FrRBCs. All patients developed grade ≥3 hypoxia and heart failure, and 4 developed grade ≥3 hypertension. The ejection fraction of the left ventricle assessed by echocardiography was significantly reduced in 3 patients. Peak creatinine levels were >4 times above the baseline and estimated glomerular filtration rates were reduced to <30 mL/min/1.73 m2. One patient received plasma exchange, while the remaining 4 responded to treatment with diuretics and cardiovascular agents. Hematological parameters normalized within a median duration of 91 days after the development of HA-FrRBCs. Renal and cardiac functions gradually improved, even though renal function did not return to the baseline. HA-FrRBCs associated with cardiac and renal impairments may represent a thrombotic microangiopathy syndrome and are a delayed complication of HDC/AHSCT. The close monitoring of laboratory abnormalities and persistent treatment with cardiovascular agents and diuretics are the mainstay for the management of this condition.

Keywords: Autologous hematopoietic stem cell transplantation; Cardiac injury; Fragmented red blood cells; High-dose chemotherapy; Renal injury; Thrombotic microangiopathy syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anemia, Hemolytic / etiology*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Creatinine / blood
  • Disease-Free Survival
  • Echocardiography
  • Erythrocytes / cytology
  • Erythrocytes / metabolism*
  • Female
  • Heart Ventricles / diagnostic imaging
  • Heart Ventricles / physiopathology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hemoglobins / analysis
  • Humans
  • Lymphoma / mortality
  • Lymphoma / pathology
  • Lymphoma / therapy*
  • Male
  • Middle Aged
  • Renal Insufficiency / etiology
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Hemoglobins
  • Creatinine